SPRO

Spero Therapeutics, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-26

Figures on this page computed 2026-11-08 12:48 UTC

Last close

1.07USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-03-26

6.9xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-126192
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-26
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-126192
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
- 10-Q for 2025, filed 2026-08-12
- 10-K for 2025, filed 2026-03-26
- 10-Q for 2025, filed 2026-08-12
The filing itself
12.8%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-126192
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
The filing itself
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-126192
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-126192
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-Q for 2025, filed 2026-08-12
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

5 of 6 traits placed on the market's range. Nothing sits below its sector's middle.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

2.06x

-0.20x

n/a

0.15x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

3 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-26

Sales2.06x
Its own average over 10 years, 32.4M.
Profit-0.20x
Its own average over 10 years, -41.9M.
Free cash flown/a
Its own average over 5 years, -49.5M.
Debtn/a
Its own average over 0 years.
Price0.15x
Its own average over 10 years, 7. Market data, 2026-11-04

Profit is furthest from its own average, at -0.20 times.

Sales is 2.06 times its own 10-year average; Profit is -0.20 times its own 10-year average; Price is 0.15 times its own 10-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-26

Sales against its own 10-year average2.06
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-126192
Reported in
USD
The filing itself
Profit against its own 10-year average-0.20
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-126192
Reported in
USD
The filing itself
Free cash flow against its own 5-year averagen/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-126192
Reported in
USD
The filing itself
Debt against its own 0-year averagen/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-126192
Reported in
USD
The filing itself
Price against its own 10-year average0.15Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD